CytoSorbents announces regulatory approval of CytoSorb in Taiwan

CytoSorbents announces the regulatory approval of CytoSorb in Taiwan by the Taiwan Food and Drug Administration or TFDA The approved indications include the extracorporeal removal of cytokines bilirubi , and myoglobi from a patient’s circulating blood. The removal of the antithrombotic drugs Brilinta or ticagrelor, AstraZeneca, and Xarelto during cardiothoracic surgery is also approved, with the goal of reducing perioperative bleeding. CytoSorb will be distributed throughout Taiwan by Hemoscien Corporation. Ms. Bettina Sabisch, Vice President of International Distributor Sales at CytoSorbents stated, “We are thrilled to announce this milestone which underscores the value and efficacy of our CytoSorb therapy and was achieved after navigating a long and complex approval process. We look forward to collaborating with Hemoscien and leveraging their long-standing customer relationships in Taiwan to bring this innovative therapy to patients in need.”